Otsuka Pharmaceutical Co., Ltd.
2-9 Kanda Tsukasa-cho
Chiyoda-ku
Tokyo
101-8535
Tel: 03-3292-0021
Website: http://www.otsuka.co.jp/
Email: wwwadmin@tky.otsuka.co.jp
174 articles with Otsuka Pharmaceutical Co., Ltd.
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
The fixed-dose combination was being evaluated in adults with intermediate and high-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
-
Astex and Otsuka Announce Results of the Phase 3 ASCERTAIN Study of the Novel Oral Cedazuridine/Decitabine Fixed-Dose Combination (ASTX727) in Patients with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
6/6/2019
Astex Pharmaceuticals, Inc. announce top-line results from the ASCERTAIN phase 3 study evaluating cedazuridine and decitabine fixed-dose combination (ASTX727) vs decitabine IV in adults with intermediate and high-risk MDS or CMML.
-
Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research
5/21/2019
Leading biopharmaceutical organizations join Project Baseline initiative to engage more patients and clinicians in research and speed evidence generation
-
Verily announced a strategic collaboration deal with Novartis, Otsuka, Pfizer, Sanofi and six major health systems.
-
National Kidney Foundation Honors Otsuka Pharmaceutical Company, Ltd. with 2019 Spring Clinical Meetings Corporate Innovator Award
5/2/2019
Otsuka Pharmaceutical Company, Ltd. has been selected to receive the 2019 Corporate Innovator Award from the National Kidney Foundation (NKF) at the 2019 Spring Clinical Meetings in Boston.
-
Denmark’s H. Lundbeck and Japan’s Otsuka Pharmaceutical announced that their brexpiprazole failed to meet its primary endpoint in two Phase III clinical trials to treat manic episodes in patients with bipolar I disorder.
-
Avanir Pharmaceuticals, Inc. Reaches Agreement in Principle with U.S. Department of Justice Regarding NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) 20mg/10mg capsules
2/13/2019
Avanir Pharmaceuticals, Inc., an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd., has reached an agreement in principle to resolve an investigation by the United States Department of Justice related to certain of Avanir's sales and marketing practices for its product NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) 20mg/10mg capsules prior to 2017.
-
Data Demonstrate Safety and Efficacy of Brexpiprazole in Patients with Schizophrenia Experiencing Severe Psychotic Symptoms
10/26/2018
The Severity of Schizophrenia Symptoms Can Be a Significant Predictor of Poor Treatment Outcomes
-
Otsuka and Proteus Digital Health Announce Expanded Collaboration Agreement to Advance Digital Medicines for Mental Health
10/11/2018
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Proteus Digital Health (Proteus) today announce the signing of an expanded global collaboration agreement that will strengthen the relationship between the two companies for the further development and commercialization of a portfolio of medicines including the ABILIFY MYCITE® (aripiprazole tablets with sensor) offering, which received NDA approval from the U.S. Food and Drug Administration in November 2017.
-
Apotheker Group Executive Search and Advisory Services Firm Celebrates its Launch and Honors Recently Appointed ACMA Board of Governors
9/28/2018
Apotheker Group, Search and Advisory, an Executive Search & Advisory firm specializing in the life sciences industry, is hosting an invite-only event on Thursday, October 4th, 2018 at the Dream Downtown Hotel in Manhattan, NY to celebrate its recent launch as well as the newly appointed ACMA Board of Governors.
-
Otsuka Pharmaceutical Completes Acquisition of Visterra
9/4/2018
Visterra will operate as a wholly owned subsidiary of Otsuka America, Inc., which is a U.S. holding company and a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd. of Japan.
-
Astex Pharmaceuticals, a member of the Otsuka group of companies, and Otsuka Pharmaceutical, indicated their guadecitabine (SGI-110) missed its co-primary endpoints in acute myeloid leukemia (AML).
-
Otsuka Pharmaceutical to Acquire Visterra
7/11/2018
Otsuka will acquire Visterra for approximately USD 430 million in an all-cash transaction.
-
Otsuka Pharmaceutical, based in Tokyo, Japan, is acquiring Waltham, Massachusetts-based Visterra for $430 million in cash. The deal is expected to close in the third quarter of this year.
-
Sofinnova Partners Announces the Sale of ReCor Medical to Otsuka Holdings
7/10/2018
Sofinnova Partners today announced that Otsuka Holdings is acquiring its portfolio company ReCor Medical.
-
Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer's Disease
5/23/2018
Otsuka Pharmaceutical Company, Ltd. (Otsuka) and Lundbeck announce that the two companies’ third clinical Phase 3 study of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type will commence in June.
-
Otsuka Awarded Grant to Advance Development of Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid
1/29/2018
Otsuka announce that the latter has been awarded a grant for up to US $10 million from the Bill & Melinda Gates Foundation to advance clinical development of Otsuka’s investigational compound to treat tuberculosis (TB), OPC-167832, in combination with delamanid as the backbone of a pan-TB regimen in line with the World Health Organization’s (WHO) Target Regimen Profiles (TRP).
-
Otsuka and X-Chem Enter Into a Drug Discovery Research and License Collaboration
12/20/2017
Under the terms of the agreement, X-Chem will utilize its DNA-encoded library (DEXTM) screening and informatics platform to search for novel drug leads for several Otsuka discovery targets.
-
GW Pharma, Otsuka Satvex Deal Terminated
12/13/2017
As a result, GW has now reacquired full ownership of the development and commercialization rights to the product in the U.S. market.